Document is current
Any future updates will be listed below
-
Authors
Goldwirt, Lauriane https://orcid.org/0000-0001-9741-803X
Louveau, B.
Baroudjian, B.
Allayous, C.
Jouenne, F.
Da Meda, L.
Vu, L.-T.
Sauvageon, H.
Herms, F.
Delyon, J.
Lebbé, C.
Mourah, S.
- License Information
-
More Information
Article History
Received: 5 January 2021
Accepted: 15 May 2021
First Online: 31 May 2021
Declarations
:
: L. Goldwirt declares a consulting role for Pfizer. B. Baroudjian declares honoraria from BMS, MSD, Novartis, Pierre Fabre and travel accommodations from BMS and Pierre Fabre. J. Delyon declares travel accommodations from Pierre Fabre and Roche. C. Lebbe declares a consulting role for Amgen, BMS, MSD, Novartis and Roche, research funding from BMS and Roche, honoraria from Amgen, BMS, Incyte, MSD, Novartis, Pfizer, Pierre Fabre and Roche and travel accommodations from BMS. S. Mourah declares a consulting role for Novartis, Biocartis and Roche and research funding from Roche, Novartis, BMS and Biocartis. All remaining authors have declared no conflicts of interest.
: MelBase (NCT02828202) is a clinical database approved by French ethics committee (CPP Ile-de-France XI, n°12,027, 2012) and dedicated to the follow-up of advanced and metastatic melanoma patients. Written informed consent was obtained from all patients.
